Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » More People Have Cholesterol Levels Above Optimum
Uncategorized

More People Have Cholesterol Levels Above Optimum

By medwebFeb 1, 2006
Share
Facebook Twitter Email

February 7, 2006

More People Have Cholesterol Levels Above Optimum

CHICAGO—An estimated 63 million adults have low-density lipoprotein cholesterol (LDL-C) levels higher than what would be ideal as recommended by the National Institutes of Health.

Of that group, 38 million are people with health conditions that put them at increased risk for cardiovascular disease.

These findings, by Stephen D. Persell, MD, MPH, and co-researchers at Northwestern University’s Feinberg School of Medicine, are reported in the February issue of the Journal of General Internal Medicine. Dr. Persell, who led the study, is assistant professor of medicine at the Feinberg School.

The study, which compared 2001 NIH cholesterol level targets with revised, more stringent, optimal targets issued in 2004, found that 10 million more adults had LDL-C (“bad cholesterol”) levels above the new targets.

The new guidelines recommend that physicians strive to get patients’ LDL-C levels lower, particularly for those at moderately high and high risk for heart disease.

“Nationally, we are far from achieving the 2001 goals, and as new evidence leads the NIH to push optional goals down further, the gap between what we believe to be ideal goals and what has been achieved gets even wider,” Dr. Persell said.

Too much LDL-C can build up on the inner lining of arteries that feed the brain and heart, and in conjunction with other substances form plaques (deposits) that can clog vessels and cause a stroke or heart attack.

In combination with cardiovascular disease risk factors, such as high blood pressure, diabetes, tobacco smoking, and/or family history of heart disease, high levels of LDL-C put individuals at increased risk for heart disease.

The goal for high-risk (heart disease or diabetes) patients is an LDL-C level less than 100. However, a level of 70, rather than 100, is suggested in updated recommendations for those who are at very high risk for cardiovascular disease.

The new optional goal for those at moderately high risk is 100, compared to the 2001 goal of 130.

The study notes that despite the fact that nearly all persons in the high-risk group have LDL-C levels that are too high, 25 percent of them already use cholesterol-lowering medications, such as statins.

The study shows that many more people would need drug therapy to reach the recommended LDL-C levels, but it notes that a substantial number are unlikely to achieve these goals with standard-dose statins.

Current costs may also place those drugs out of reach for many patients. At current retail prices, a year’s supply of 40 milligrams daily of generic lovastatin can cost $450 to $700.

Costs per patient would be even higher if name-brand statins or high-dose statins and combination drug therapy are used.

The updated guidelines, published in July 2004, were based on a review of five major clinical studies of statin therapy conducted after the 2001 guidelines were released.

Dr. Persell’s co-investigators on this study were Donald M. Lloyd-Jones, MD, assistant professor of preventive medicine and of medicine; and David W. Baker, MD, associate professor of medicine and chief of general internal medicine at the Feinberg School.

This study was supported by the Division of General Internal Medicine, Northwestern University.

Share. Facebook Twitter Email

Related Posts

Mar 29, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Comments are closed.

Latest News

Self-Powered Wireless Implant Delivers Medication, Then Dissolves

Mar 30, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

The Future of IgE-Mediated Allergy Research and Treatments

Mar 29, 2023

Weintraub Appointed to Illinois Supreme Court Commission on Elder Law

Mar 28, 2023

Investigating Protein’s Role in Hearing Loss

Mar 27, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.